US/UK/Canada

Share

Contacts

  • Pia Renaudin

    • Links

    Pick a time period -
    Tags ( Active)

    New review article highlights Nevisense effectiveness in identifying malignant skin lesions

    STOCKHOLM, SWEDEN, - January 28, 2025 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that a new review article has been published highlighting the performance of Nevisense in identifying malignant skin lesions. The article titled "Progressive approaches in oncological diagnosis and surveillance: real-time impedance-based techniques and advanced algorithms” was written by researchers at George Washington University, Washington DC, USA, and has been published in the journal "Bioelectromagnetics."

    Recalculation of warrants of series TO 2 following rights issue

    In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April 2024, the number of shares that each warrant entitles the holder to subscribe for and the subscription price shall be recalculated following rights issues. Accordingly, SciBase Holding AB (the "Company" or "SciBase") has carried out a recalculation of warrants of series T0 2 due to the rights issue of units that was announced on November 12, 2024. Following the completed recalculation, SciBase can confirm that the number of shares that each warrant

    Nevisense (EIS) included in updated German (S1) imaging guidelines.

    Stockholm, SWEDEN. January 23, 2025 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that updated German guidelines for imaging (S1) has been published today. Nevisense (EIS - or “MIS - Mikroelektrische Impendanzspektroskopie”) is mentioned as a technology for detecting Melanoma and Non-Melanoma skin cancer as well as the future potential in Atopic Dermatitis (AD). The guidelines conclude that "If seborrhoeic keratoses and inflammatory lesions are ruled out clinically or dermatoscopically, Nevisense

    SciBase announces final outcome of directed issue and rights issue

    SciBase Holding AB (”SciBase” or the ”Company”) today announces the final outcome of the capital raise, consisting of a rights issue of units of approximately SEK 59.3 million (the “Rights Issue”) and a directed issue of units, deviating from existing shareholders' preferential rights, of approximately SEK 22.5 million (the ”Directed Issue”), that was announced on  November 12, 2024 (the ”Capital Raise”). All 16,669,624 units in the Directed Issue have been subscribed and paid for, and thus the Board of Directors of SciBase intends to resolve on allocation of units to the investors in the

    SciBase announces outcome of directed issue and preliminary outcome of rights issue

    SciBase Holding AB (”SciBase” or the ”Company”) today announces the preliminary outcome of the capital raise, consisting of a rights issue of units of approximately SEK 59.3 million (the “Rights Issue”) and a directed issue of units, deviating from existing shareholders' preferential rights, of approximately SEK 22.5 million (the ”Directed Issue”), that was announced on  November 12, 2024 (the ”Capital Raise”). All 16,669,624 units in the Directed Issue have been subscribed and paid for, and thus the Board of Directors of SciBase plans to resolve on allocation of units to the investors in the

    The Mayo Clinic, the leading US hospital, will test Nevisense in Pilot

    Stockholm, SWEDEN. January 3, 2025 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it is working with Mayo Clinic, the leading US based hospital, on pigmented lesion digital workflows with AI-driven Nevisense - the only FDA Approved device for skin cancer detection at point of care.“Melanoma is the deadliest form of skin cancer and accounts for the majority of skin cancer deaths because it can spread from the skin to other parts of the body where it becomes difficult to treat and can be fatal.

    Today the subscription period in SciBase rights issue begins

    Today, on December 27, 2024, is the first day of the subscription period in SciBase Holding AB's (“SciBase” or the “Company”) rights issue of units, consisting of new shares and warrants, which was announced on November 12, 2024 (the "Rights Issue"). One (1) unit consists of three (3) shares and three (3) warrants of series TO 3 (“Unit”). The subscription period runs until January 13, 2025. However, please note that some banks and nominees may have an earlier response deadline for subscription in the Rights Issue. Shareholders should therefore check with their bank or nominee if they have an

    SciBase letter from the CEO

    In 2024, SciBase has advanced its positions significantly and laid the foundation for continued growth, with a new organization in the US, success within the skin barrier segment and expansion into new markets.Our new organization in the US is critical to our continued development and the ability to provide more patients with access to better diagnostic methods for skin cancer. Since the second half of the year, we have strengthened the organization with several people, with both broad and deep knowledge in dermatology. They also have extensive experience in commercializing new technologies,

    SciBase publishes prospectus

    SciBase Holding AB (“SciBase” or the “Company”) announced on November 12, 2024 that the Board of Directors has resolved, subject to the subsequent approval of the Extra General Meeting, to carry out a capital raise of a total of approximately SEK 81.8 million through the issuance of so-called units (the “Capital Raise”). One (1) unit consists of three (3) shares and three (3) warrants of series TO 3 (“Unit”). The Capital Raise consists of a directed share issue of Units, with deviation from existing shareholders’ preferential rights, of approximately SEK 22.5 million (the “Directed Issue”),

    Bulletin from the extraordinary general meeting in SciBase Holding AB (publ)

    Today, an extraordinary general meeting has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance with the proposals presented in the notice to convene the meeting (which is available on the Company's website (www.scibase.com)):Amendment of the articles of associationThe general meeting resolved, in accordance with the board of directors' proposal, to amend §§ 4-5 of the articles of association, entailing that the articles of association shall be amended so that the Company's share capital shall be not less than SEK 16,440,000 and

    SciBase Announces Positive Findings in Case Study Monitoring Treatment Outcomes in Atopic Dermatitis Patient

    STOCKHOLM, SWEDEN, - November 13, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of artificial intelligence (AI)-based solutions for skin is excited to announce the publication of a case study highlighting the use of Nevisense as a skin barrier assessment device in monitoring treatment outcomes in patients with atopic dermatitis (AD). The study, conducted by a team of researchers at Koç University in Istanbul, demonstrates the potential of Nevisense to revolutionize the way AD patients are treated and monitored.Atopic dermatitis is a chronic inflammatory skin disease

    Notice to extraordinary general meeting in Scibase Holding AB (publ)

    Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to an extraordinary general meeting to be held on 13 December 2024 at 10.00 CET at Advokatfirman Schjødt, Hamngatan 27, in Stockholm. The registration to the meeting will open at 9.30 CET.Right to participate and notice of participation A shareholder who wishes to participate at the extraordinary general meeting must: (i) be recorded in the share register maintained by Euroclear Sweden AB on 5 December 2024, and(ii) notify the Company of its intention to participate by post

    SciBase announces collaboration for prediction of atopic dermatitis in infants

    November 12, 2024 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today its engagement in a collaboration with the SKIN Research Group of the Department of Dermatology at the Vrije Universiteit Brussel (VUB)/ University hospital in Brussels (UZ Brussels) for a study geared toward predicting atopic dermatitis (a special form of eczema) and concomitant atopic diseases, such as asthma and hay fever in infants.SciBase is excited to announce a new collaboration aimed at revolutionizing early detection of

    Interim report January 1 – September 30, 2024

    January 1 – September 30, 2024The third quarter in figures · Net sales were TSEK 8,408 (7,248), +16%. · The loss after tax was TSEK 17,753 (12,786). · The loss per share was SEK 0.08 (0.11). · The cash flow from current operations was negative in the amount of TSEK 16,745 (17,827). · The gross margin was 75.7% (68.2%). · Electrode sales volume increased by 2% and was 17,210 (16,922) units. Repeat sales of electrodes to existing customers decreased by 7% as Q3-23 included large electrode orders prior to a price increase. January - September in figures · Net sales

    SciBase decides on a directed issue of approximately SEK 22.5 million and a rights issue of up to approximately SEK 59.3 million

    The Board of Directors of SciBase Holding AB (publ) (“SciBase” or the “Company”) has today decided to carry out a capital raise totaling approximately SEK 81.8 million (the “Capital Raise”). The Capital Raise consists of a directed issue of so-called units, consisting of shares and warrants of series TO 3, deviating from existing shareholders’ preferential rights, of approximately SEK 22.5 million to Maria Anderkvist, Praktikerinvest Aktiebolag, Victor Anderkvist, Haga Gruppen Holding AB, Kåre Gilstring, Ulf Andersson, Johan Gyllenswärd AB, Sven Holmgren, Max Leitgeb, Opthron Förvaltning

    SciBase initiates sales collaboration in Italy

    SWEDEN, - October 30, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announces today the collaboration with Kilabs srl, an Italian Company with expertise in dermatology, which now will be able to offer access to better diagnostics of skin cancer in Italy.Kilabs is dedicated to advancing research, development and access to cutting-edge solutions in specialized medical fields. SciBase will adapt Nevisense for the Italian market, which is a regulatory prerequisite for the launch which is expected to take place

    SciBase continues US expansion and will attend Fall Clinical conference

    SWEDEN, - Oct 21, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders will attend a leading US dermatology conference, Fall Clinical, to further enhance the clinical adoption and market expansion of Nevisense. The Fall Clinical conference attracts more than 1,100 clinicians looking to bridge gaps within the detection and diagnosis of melanoma clinical pathway. The conference offers comprehensive workshops and sessions led by top dermatology experts highlighting the latest advances in the diagnoses and treatment of

    Nomination Committee appointed for SciBase Holding’s Annual General Meeting in 2025

    The following people have been appointed as members of SciBase Holding’s nominating committee for the Annual General Meeting in 2025: Anders Bladh (Ribbskottet AB), Fredrik Mattsson (Ejendals AB) Dharminder Chahal (VanHerk Group), Jesper Høiland (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on June 13, 2024.The Annual General Meeting of SciBase Holding AB (publ) will be held on May

    SciBase announces sale of Nevisense to NIH (US)

    SWEDEN, - Sept 27, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], pioneering prevention and prediction in dermatology disorders is pleased to announce the completion of a milestone sale of Nevisense, a leading skin barrier research device, to the National Institutes of Health (NIH), one of the world’s foremost medical research centers and a part of the U.S. Department of Health and Human Services. This sale represents a major milestone for SciBase and demonstrates the high quality and innovative nature of Nevisense for research.The device will be used to conduct research on the

    SciBase expands to new market in Pennsylvania and receives first order from large dermatology practice

    SWEDEN, - Sept 26, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], pioneering prevention and prediction in dermatology announces today a partnership with Seraly Dermatology in Pittsburgh, Pennsylvania. The strategic collaboration will allow SciBase to continue to broaden access of the Nevisense test to patients across the US, and further their commitment to the early detection of melanoma, when the disease is almost 100% curable. Seraly Dermatology will integrate several Nevisense systems into their skin cancer detection workflow.“Melanoma is the deadliest form of skin cancer and

    New US Consensus Report supports Nevisense

    · Consensus reached by top US clinicians assessing technologies for melanoma detection and management · The report concludes that the Nevisense AI-driven technology can significantly enhance early melanoma detectionSWEDEN, - Sept 02, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], pioneering prevention and prediction in dermatology announces that key US clinicians and scientists reached consensus on Nevisense and how it can significantly enhance the diagnostic assessment and clinical decision-making for early melanoma at point of care. Nevisense is an AI-driven, non-invasive

    SciBase changes Certified Adviser to Carnegie Investment Bank AB (publ).

    STOCKHOLM, SWEDEN, 21 August 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase], a leading developer of augmented intelligence-based solutions for skin, hereby announces change of Certified Adviser from Vator Securities to Carnegie Investment Bank AB (publ).SciBase has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will assume the role of Certified Adviser effective from September 1, 2024. Until then, Vator Securities will continue to act as the Certified Adviser for the company.

    Interim report

    January 1 – June 30, 2024The second quarter in figures · Net sales were TSEK 6,641 (5,085), +31%. · The loss after tax was TSEK 15,050 (11,352). · The loss per share was SEK 0.08 (0.16). · The cash flow from current operations was negative in the amount of TSEK 15,179 (13,054). · The gross margin was 69.1% (65.3%). · Electrode sales volume increased by 24% and was 14,106 (11,330) units. Repeat sales of electrodes to existing customers increased by 22%. January - June in figures · Net sales were TSEK 12,699 (10,234), +24%. · The loss after tax was TSEK 25,911 (

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media

    Youtube